Madrigal Pharmaceuticals Inc
Closed
SectorHealthcare
531.75 -0.16
Overview
Share price change
24h
Min
529.14
Max
546.26
Income | 36M -58M |
|---|---|
Sales | 53M 364M |
EPS | -1.99 |
Profit margin | -15.906 |
Employees | 915 |
EBITDA | 30M -56M |
Next Earnings | 3 lis 2026 |
|---|
Market Cap | -208M 13B |
|---|---|
Previous open | 531.91 |
Previous close | 531.75 |
News Sentiment
By Acuity
26%
74%
55 / 339 Ranking in Healthcare
Madrigal Pharmaceuticals Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Madrigal Pharmaceuticals Inc Forecast
Sentiment
By Acuity
55 / 339 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.